Creative Life Science Co Ltd

Creative Life Science maintains a debt-to-equity ratio of 0.66 and a current ratio of 1.84, indicating moderate leverage and sufficient short-term liquidity to cover obligations. Free cash flow of TWD 146.35 million supports operational flexibility, though net cash is negative after subtracting total debt, signaling potential liquidity risk. Profitability metrics show a return on equity (ROE) of 15.3% and return on assets (ROA) of 7.21%, outperforming the median ROE of 10.5% and ROA of 5.1% for the Life Sciences Tools & Services industry. Gross margin of 40.6% (TWD 349.54 million gross profit on TWD 860.58 million revenue) aligns with industry norms, but operating margin of 12.5% (TWD 107.81 million) suggests moderate cost control. The company operates in a single geographic market, Taiwan, where it distributes products across pharmaceuticals, biotechnology, and medical diagnostics. Revenue concentration in one region exposes it to local regulatory and economic risks. No disclosed segment data prevents analysis of product-line profitability. Outlook for FY2024 shows revenue growth of 4.2% year-over-year, driven by expanded IVD product agency and increased demand in clinical diagnostics. Capital expenditure of TWD -33.79 million indicates asset optimization rather than expansion. Risk assessment highlights medium liquidity risk due to negative net cash and low dilution risk, with no near-term share issuance plans disclosed. Adjustments in custom valuations reflect conservative debt assumptions and no material off-balance-sheet liabilities. Recent filings include a 2023 annual report disclosing revenue growth and product diversification, and a 2024 Q1 earnings call noting stable demand in food safety testing. No material litigation or regulatory actions were reported.